- Home
- CTNM vs KT Comparison
CTNM vs KT Comparison
Compare CTNM & KT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTNM
- KT
- Stock Information
- Founded
- CTNM 2009
- KT 1981
- Country
- CTNM United States
- KT South Korea
- Employees
- CTNM N/A
- KT N/A
- Industry
- CTNM
- KT Telecommunications Equipment
- Sector
- CTNM
- KT Telecommunications
- Exchange
- CTNM Nasdaq
- KT Nasdaq
- Market Cap
- CTNM 114.1M
- KT N/A
- IPO Year
- CTNM 2024
- KT 1999
- Fundamental
- Price
- CTNM $3.87
- KT $19.32
- Analyst Decision
- CTNM Strong Buy
- KT
- Analyst Count
- CTNM 4
- KT 0
- Target Price
- CTNM $23.75
- KT N/A
- AVG Volume (30 Days)
- CTNM 86.8K
- KT 1.3M
- Earning Date
- CTNM 05-16-2025
- KT 05-19-2025
- Dividend Yield
- CTNM N/A
- KT 3.17%
- EPS Growth
- CTNM N/A
- KT N/A
- EPS
- CTNM N/A
- KT 1.29
- Revenue
- CTNM N/A
- KT $17,892,154,217.00
- Revenue This Year
- CTNM N/A
- KT $6.12
- Revenue Next Year
- CTNM N/A
- KT N/A
- P/E Ratio
- CTNM N/A
- KT $28.34
- Revenue Growth
- CTNM N/A
- KT 0.21
- 52 Week Low
- CTNM $3.69
- KT $13.07
- 52 Week High
- CTNM $22.00
- KT $20.28
- Technical
- Relative Strength Index (RSI)
- CTNM N/A
- KT 58.88
- Support Level
- CTNM N/A
- KT $16.25
- Resistance Level
- CTNM N/A
- KT $20.28
- Average True Range (ATR)
- CTNM 0.00
- KT 0.38
- MACD
- CTNM 0.00
- KT 0.03
- Stochastic Oscillator
- CTNM 0.00
- KT 56.16
About CTNM Contineum Therapeutics Inc. Class A Common Stock
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.